Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RR0034 | Human STAT1 Prom/Luciferase/Hyg Reporter Stable Cell Line-HeLa | Inquiry |
| CSC-DC015280 | Panoply™ Human STAT1 Knockdown Stable Cell Line | Inquiry |
| CSC-RK0291 | Human STAT1 Knockdown Cell Line-HeLa | Inquiry |
| CSC-SC015280 | Panoply™ Human STAT1 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT2170 | Human STAT1 Knockout Cell Line-A549 | Inquiry |
| CLOE-0592 | Human STAT1 Insect Cell Lysate | Inquiry |
| CSC-RT2745 | Human STAT1 Knockout Cell Line-HEK293 | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD15639Z | Human STAT1 adenoviral particles | Inquiry |
| LV26831L | human STAT1 (NM_007315) lentivirus particles | Inquiry |
| LV26832L | human STAT1 (NM_139266) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH419384 | shRNA set against Human STAT1 (NM_007315.3) | Inquiry |
| SHH419388 | shRNA set against Mouse STAT1 (NM_009283.4) | Inquiry |
| SHH419392 | shRNA set against Rat STAT1 (NM_032612.3) | Inquiry |
| SHL040110 | shRNA set against Rat Stat1(NM_001034164.1) | Inquiry |
| SHW001071 | shRNA set against Chicken STAT1 (NM_001012914) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCB191393 | Rabbit STAT1 ORF clone (XM_008258841.1) | Inquiry |
| CDCH402631 | Mouse STAT1 ORF clone(NM_009283.4) | Inquiry |
| CDCS413162 | Human STAT1 ORF Clone (BC002704) | Inquiry |
| CDFR004387 | Rat Stat1 cDNA Clone(NM_001034164.1) | Inquiry |
| CDFR012439 | Rat Stat1 cDNA Clone(NM_032612.3) | Inquiry |
| MiUTR1M-11308 | STAT1 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-11309 | STAT1 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-03470 | STAT1 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-03471 | STAT1 miRNA 3'UTR clone | Inquiry |
| CDCB162546 | Chicken STAT1 ORF Clone (NM_001012914) | Inquiry |
| CDCH086676 | Mouse Stat1 ORF clone (NM_001205313.1) | Inquiry |
| CDCH402632 | Mouse STAT1 ORF clone(NM_001205314.1) | Inquiry |
| CDCR371416 | Rat Stat1 ORF Clone(NM_001034164.1) | Inquiry |
| CDCR380038 | Rat Stat1 ORF Clone(NM_032612.3) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CC-1355 | STAT1 Easy KO Kit | Inquiry |
DNA-binding transcription factor Signal Transducer and Activator of Transcription 1 (STAT1) encodes two isoforms of STAT1, a and b. STAT1a is a transcriptional activator playing an important role in signaling responses to a wide variety of cytokine and growth factors, whereas STAT1b functions as a dominant negative inhibitor. Cytoplasmic Stat1 is activated by tyrosine phosphorylation, typically by members of the JAK kinase family, which leads to its translocation to the nucleus and subsequent binding to target DNA sequences. STAT1 performs multiple important biological functions in normal cells, such as cell growth inhibition, cell death promotion, cell differentiation regulation, and immune system stimulation.
Results generated from most STAT1 studies support the concept of STAT1 as a tumor suppressor. Based on the canonical role in IFNγ signaling and on studies using STAT1-/- tumor cells and mouse models, STAT1 has been classically defined as a Th1 proimmune and antitumor transcription factor. STAT1 has also been described to regulate DNA repair pathways and to be upregulated in many late-stage human cancers, including those of the glioblastoma, colon, breast, and soft tissue sarcoma. Overexpression of the IFN-STAT1 pathway is also associated with poor prognosis of different types of cancer. Especially in breast cancers, the increased IFN-STAT1 pathway activity is considered a marker to predict chemotherapy and radiotherapy resistance.
In terms of mechanism, tumour suppression by STAT1 occurs at multiple levels: tumour cell-intrinsic growth control and cross-talk with other cells to regulate cancer immunoediting and suppress angiogenesis. STAT1 regulates cell death through transcription-dependent and transcription-independent mechanisms. As a transcription factor, STAT1 directly regulates the expression of many genes, such as BCL2 and caspases, as well as interacting with other proteins, such as TRADD and p53. Similar mechanisms by which STAT1 promotes cell death are also detected in multiple cancer cell types. Furthermore, STAT1 is considered to be a negative regulator of tumor angiogenesis in many types of cancer. For example, in non-small cell lung cancer cells, IL-27 induces mesenchymal to epithelial transition and inhibits the production of pro-angiogenic factors, such as β-catenin/N-cadherin, vimentin, E-cadherin, VEGF, CXCL5, and IL-8/CXCL8, in a STAT1-dominant pathway.
Figure 1. Tumour suppressive functions of STAT1. (Meissl K, et al. 2017)
However, the role of STAT1 as a tumor suppressor remains controversial. Aberrant STAT1 activation has been detected in some types of human cancer, such as pleural mesothelioma, head and neck cancer, breast cancer, and lymphoma. The silencing of STAT1 can enhance cell apoptosis induced by chemotherapeutic agents and radiation in renal cell carcinoma and breast cancer. Some studies reported contradictory observations indicating that patients with high expression of STAT1 and/or p-STAT1 in cancer tissues experience worse clinical outcomes in comparison to patients with low levels of STAT1 and/or p-STAT1, such as sarcoma, breast cancer and Wilms’ tumor. Other studies showed that a high p-STAT1 expression or STAT1 mRNA level is associated with poor overall survival and an advanced clinical stage in breast cancer and glioblastoma multiforme patients. In vivo studies further supported the role of STAT1 in promoting carcinogenesis.
The role of STAT1 in tumourigenesis is complex, since its functions are not restricted to tumour cells, but extend to different compartments of the tumour microenvironment. A more detailed mechanistic analysis of the tumour cell-intrinsic and extrinsic functions of STAT1 and their contribution to carcinogenesis will help to fully exploit the diagnostic and therapeutic potential of STAT1. The association of high STAT1 expression and/or activity with therapy resistant tumour types indicates that selective STAT1 inhibitors may be useful in cancer therapy. Selective inhibitors for STAT3 and STAT5 are rapidly advancing and STAT1 inhibitors are within reach. Inhibitors will help clarify the multifaceted functions of STAT1 in tumourigenesis and may open future paths in cancer therapy.
References: